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Implantable
Cardioverter-Defibrillators
for Primary Prevention
of Sudden Death
The Quest to Identify
Patients Most Likely to Benefit*
Alfred E. Buxton, MD
Boston, Massachusetts
Last week, an 83-year-old man was transferred to our
service from another hospital for placement of an implant-
able cardioverter-defibrillator (ICD). He was hospitalized at
the other institution because he had developed a retroperi-
toneal bleed while anticoagulated because of atrial fibrilla-
tion. He had a nonischemic dilated cardiomyopathy (ab-
sence of significant coronary obstructions had been proven
by an earlier catheterization). His ejection fraction (EF) was
20%, and his New York Heart Association functional class
was III. He had a history of chronic obstructive lung disease,
and a serum creatinine level of 1.8 mg/dl, and no symptom-
atic ventricular tachyarrhythmia had been documented.
Because nonsustained ventricular tachycardia was seen on
telemetry, a consulting cardiologist told the patient’s family
that he “needed” an ICD.
See page 1647
It was unfortunate that the cardiologist said that the
patient needed an ICD, because this wording conveyed to
the family the idea that the ICD would save his life. It
would have been far more appropriate for the physician to
explain to the patient and his family what his estimated
survival chances over a 2-year to 3-year follow-up period
would be with versus without an ICD, as well as the likely
impact of the ICD on his quality of life. This was obviously
not done, probably because the consultant had no idea of the
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from Medtronic.patient’s estimated survival with or without an ICD. In-
stead, the consultant probably knows that several random-
ized clinical trials have demonstrated statistically significant
reductions in mortality with ICD therapy, and he believes
that current guidelines state that any patient with a left
ventricular EF 30% should receive an ICD.
This case illustrates a number of issues we face today in
trying to reduce the risk for sudden unexpected cardiac
death in patients with recognized cardiovascular disease. Let
us review some of these. First is the fact that clinical trials
must have clearly defined entry and exclusion criteria. These
criteria are then used to formulate practice guidelines.
However, patients enrolled in clinical trials have multiple
characteristics that influence their intrinsic risk for endpoints
such as sudden cardiac death. The heterogenous nature of
patients means that the average risk reduction observed with
a treatment in a clinical trial may actually not pertain to
many patients enrolled in the trial (1). A consequence of the
wide variation in risk for total mortality and sudden death of
patients enrolled in a given trial is varying survival benefit of
treatment. For example, the relative risk reduction for total
mortality with ICD therapy was 54% in the Multicenter
Unsustained Tachycardia Trial and MADIT (Multicenter
Automatic Defibrillator Implantation Trial), 31% in MADIT
II, and 23% in SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial) (2–5). However, multivariate analyses
have demonstrated that in MUSTT and MADIT II, 25%
to 30% of the study populations had 2-year total mortality
risk of 5% and 8%, respectively, and in SCD-HeFT, 20% of
the study population had 2-year mortality of 5%, without
ICD therapy (6–8). Populations with 2-year total mortality
of 5% to 8% can be expected to have a yearly sudden death
risk of 1% to 2% (a level of risk at which there is unlikely to
be significant ICD benefit). Conversely, in MADIT II and
SCD-HeFT, 20% of the study populations had 2-year
mortality of 30% to 50%. The wide variation in risk within
these trials translates into vastly different treatment effects
for a similar relative risk reduction of 20% to 30%. That is,
a subject whose baseline risk is 2% to 3% per year will see
much less absolute benefit from treatment than a person
with 15% to 20% annual risk (1).
However, estimating the potential benefit of ICD treatment
is more complex than just knowing predicted total mortality for
an individual patient, because there are multiple potential
causes of mortality, and the ICD can reduce only those deaths
that occur from ventricular tachyarrhythmias. Paradoxically,
those patients at highest mortality risk did not experience any
survival benefit from the ICDs in the randomized trials
because of 2 factors. First, multiple competing conditions lead
to nonarrhythmic death, accounting for more deaths as overall
risk increases. Second, sudden death accounts for a progres-
sively smaller proportion of mortality as overall mortality risk
increases (7,8).
Thus, there is a “sweet spot” range of mortality in which the
risk for sudden death is high enough, and competing risk for
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significant reduction in mortality. How can we best identify
those patients most likely to benefit? The published models
referred to previously are a reasonable starting point. However,
although current ICDs have not changed significantly from
those used in the randomized trials, other cardiac treatment is
very different at present compared to that used in the trials.
The use of beta-adrenergic blocking agents and other pharma-
cotherapy was not as frequent as is appropriate for patients with
abnormal left ventricular function. Modes of coronary revas-
cularization were not the same during the trials. In addition,
there may be less obvious differences between patients enrolled
in clinical trials and those in which the guidelines are applied at
present. Thus, there is a need to develop valid contemporary
algorithms to guide ICD use for the primary prevention of
sudden unexpected cardiac death.
In this issue of the Journal, Bilchick et al. (9) describe a
model to predict risk for mortality based on 2 populations of
Medicare patients who received ICDs for the primary
prevention of sudden death from 2005 to 2007. Their model
identified risk factors common to earlier models, as well as
some new variables: age 75 years, New York Heart
Association class III, chronic kidney disease, left ventricular
EF 20%, atrial fibrillation, chronic obstructive pulmonary
isease, and diabetes mellitus. In this analysis, 37% of
atients in the development cohort of approximately 18,000
CD recipients and 31% of the 28,000 patients in the
alidation cohort died over a median follow-up period of 4
ears. The 20% of patients in the highest risk group had
-year mortality of almost 40%, while the 20% in the lowest
isk group had 2-year mortality of 7%. If their model is
pplied to the patient described earlier, he would have a
rojected 2-year mortality of 65%, despite having an ICD
mplanted. Would the ICD benefit this patient? I think the
hances are small.
This study joins a growing number of similar efforts. This
ear alone, 3 other reports of models to predict mortality in
CD recipients have been published (10–12). These models
ave a number of factors in common with Bilchick et al.’s
9) model and share similar limitations. They are based on
nalyses of patients who received ICDs. Thus, they cannot
e used to estimate ICD benefit because none included
ntreated patients. Nevertheless, all identify substantial
ubgroups of ICD recipients with very high total mortality.
t seems highly unlikely that ICDs were helpful to those
atients who died within 2 years after implantation. Second,
he variables incorporated into each of these models bear no
echanistic relation to ventricular tachyarrhythmias. Thus,
hey cannot possibly target those patients with the greatest
hance to benefit from the ICD: those with the substrate to
upport ventricular tachycardia or fibrillation. Third, be-
ause the endpoint in each study is total mortality, they do
ot provide insight into a second subgroup of patients
eceiving ICDs under current guidelines: those at low risk
or ventricular tachyarrhythmias despite low EFs. In previ-ous analyses, these patients have accounted for at least 25%
of patients meeting guidelines for primary prevention ICDs.
Two requirements must be met to validate the ability of
models to identify patients at low risk for sudden death despite
reduced EFs. First, a prospective study format must be used
along with uniform programming of ICD detection criteria to
accurately understand the meaning of “appropriate” ICD
discharges, or a matched untreated control group must be
compared with ICD recipients. Second, tests capable of iden-
tifying patients having 1 or more of the electrophysiologic
substrates to support re-entry, triggered activity, or automatic-
ity in ventricular muscle must be incorporated into the model.
One such test has previously been validated as a method to
guide ICD therapy: programmed electrical stimulation (elec-
trophysiologic testing) (13). However, electrophysiologic test-
ing must be supplemented by other markers of arrhythmic risk,
such as left ventricular hypertrophy, because not all ventricular
tachyarrhythmias result from re-entry.
There is a message here. Multiple investigators and
clinicians in the United States and other countries realize
that current guidelines are inadequate to use ICDs in the
most appropriate, cost-effective manner for primary preven-
tion of sudden death. They must be changed. However,
change will require the completion of 1 or more randomized
controlled trials that demonstrate superiority (or at least
noninferiority) of a multivariate model approach to the
current standard. In our current climate, clinicians are
extremely hesitant to randomize patients to a therapy that
goes against current guidelines. The conduct of a successful
randomized clinical trial will require the cooperation of
multiple governmental agencies and third-party payers,
together with informed clinicians. Clinical cardiologists in
turn must be willing to take the time to explain to their
patients what ICDs can and cannot do. Clinicians must also
be able to estimate patients’ risk for mortality with and
without ICDs. This is the next logical step, and we must
take it. We owe it to the practice of medicine. We owe it to
our patients!
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